| Assessment Status | Rapid Review Complete |
| HTA ID | 23065 |
| Drug | Dapagliflozin |
| Brand | Forxiga® |
| Indication | Dapagliflozin (Forxiga®) is indicated in adults for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40%. |
| Assessment Process | |
| Rapid review commissioned | 11/10/2023 |
| Rapid review completed | 21/11/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that dapagliflozin for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40% be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
